AzTrials
AzTrials

Peripheral Arterial DiseaseHSP70NCT04743128

Exercise on Expression of Heat Shock Protein 70 in Arterial Risk

A study testing Exercise in people with Peripheral Arterial Disease, run by Universidad Popular Autónoma del Estado de Puebla at 1 site in Mexico.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Introduction: Atherosclerotic Peripheral Arterial Disease (PAD) is the leading cause of mortality in the western world. To maintain homeostasis of the vessel wall, vascular cells produce a high level of heat shock proteins (HSP), among which is Hsp70, to stimulate innate immunity and face stress. Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
Conditions the study is for
Peripheral Arterial Disease
What is being tested?
Exercise
Could I receive a placebo?
No, everyone receives an active treatment
How many people
32 participants
Where
1 siteMexico
Study dates
3 Jun 2019to 30 Aug 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • ABI cut point from 0.91 to 0.99
  • Age, from 40 to 75 years old
  • Both genders

Who cannot join

  • Unable to perform Bruce's stress test
  • Presence of fractures or sprains in the last 3 months
  • Diagnosis of diabetes, heart disease, angina pectoris or heart attack

Trial locations and contacts

1 site in 1 country.

Mexico1 site
  • UPAEP

    Puebla City, 72410

Other trials in Mexico

About this study

Official title: Impact of Exercise on Expression of Hsp70 in Individuals at Risk of Peripheral Arterial Disease. A Randomised Trial

Introduction: Atherosclerotic Peripheral Arterial Disease (PAD) is the leading cause of mortality in the western world. To maintain homeostasis of the vessel wall, vascular cells produce a high level of heat shock proteins (HSP), among which is Hsp70, to stimulate innate immunity and face stress.

Methods: This is a clinical trial where 260 individuals were evaluated by a screening test employing the Ankle-Arm Index (ABI), 220 of them were not within risk value (0.91 to 0.99 mmHg). In the clinical trial, 32 individuals were included. A control group and an experimental group were formed. Aerobic exercise intervention was performed for 12 weeks. The level of Hsp70 was evaluated, physical and clinical measurements were applied at the beginning and at the end of the trial.

Read the detailed description

The objective of the study is to determine the level of serum expression of the HSP70 protein in individuals at risk of atherosclerotic peripheral arterial disease, after an intervention of moderate exercise.

Atherosclerotic Peripheral Arterial Disease (PAD) is a systemic disease that causes obstruction of arterial blood flow and is a significant cause of morbidity and mortality worldwide 1.

Patients with PAD have a three times greater risk of myocardial infarction, stroke and death than those without the disease. However, more than 50% of patients are asymptomatic; so the disease remains underdiagnosed. 2 It is estimated that 202 million people in the world are affected with PAD, 45 million of them die from coronary or cerebrovascular disease in a range of ten years. The current prevalence of PAD in Mexico is 10% of the general population.3 The disease is strongly related to modifiable risk factors (blood pressure, sedentary lifestyle, baseline glycemia, cholesterol, and obesity) and unhealthy lifestyle (tobacco, physical inactivity, food and psychosocial stress), which increases the risk of acquiring the disease up to 17.2 times 4, 5, 6 Increased membrane permeability leads to the accumulation and modification of proteins, lipids and lipoproteins in the endothelium. The accumulation of pro-inflammatory molecules such as chemo-tactical monocyte protein 1 (MCP-1), intracellular adhesion molecules (ICAM-1), vascular cell adhesion (VCAM-1) and higher nitro-tyrosine content are also generated. 7 Macrophages are active in response to the spread of the inflammatory response and bind to low-density lipoprotein (LDL) receptors that had internalized.

Macrophages secrete pro-inflammatory cytokines resulting in the recruitment and activation of additional immune cells at the site of the lesion, amplifying the immune response and promoting the development of complex and advanced plaques that become mature atherosclerotic plaques.8 The Ankle Arm Index (ABI) is the non-invasive gold standard accepted for both the diagnosis and evaluation of the severity of this disease. The cut-off point for the diagnosis of PAD is an ABI of less than 0.90 at rest, regardless of the Framingham Risk Score, being 95% sensitive in the detection of PAD. 9, 10 To maintain homeostasis on the vessel wall, vascular cells produce a high level of heat shock proteins (HSP) 11. These types of stress proteins are cytoprotective agents that promote cell survival during stressors. 12 The reduction of HSP intracellular expression is also related to PAD, cardiovascular diseases and metabolic syndrome, where they are greatly diminished. 10 HSP are normally intracellular proteins, but when released at an extracellular level, they exert an immune response.13 The most thermo-sensitive and highly inducible HSP belongs to the 70 kilodalton (kDa) family, as established by Mizzen et al., In 1998 (figure 1). It is believed that extracellular Hsp70 (eHsp70) stimulates innate immunity and acts as a danger signal. Serum Hsp70 has been detected in the peripheral circulation of apparently healthy individuals and increases in response to different stressors, including exercise. 12, 14

Figure 1. Schematic representation of the molecular structure of HSP70. Adapted from Carrasco L. et al. 15 Exercise increases HSP levels primarily through reactive oxygen species (ROS), elevated temperature, hormones, calcium fluxes or mechanical tissue deformation.16 It has been shown that the concentration of Hsp70 increases after performing both acute and long-term exercises, reaching levels that remain high, but once its protective action decreases both at intra and extra-cellular levels.17 Exercise exerts beneficial effects against atherosclerosis by increasing circulating endostatin, which inhibits the development of atherosclerotic plaque by blocking angiogenesis in plaque tissue.18 Isotonic contractions of the type of resistance exercise (aerobic) tend to lead to increases in Hsp70 levels, as opposed to eccentric exercise. With repetitive exercise, an induced increase in this protein is maintained, while the initial response of other HSPs to exercise decreases as training progresses.16 Regular exercise initiates long-term processes of adaptation of muscle metabolism, cardiovascular system and immuno-modulatory effects that are largely considered beneficial; There is evidence that during exercise, Hsp70 is released into human circulation in association with exosomes, specifically with aerobic exercise.19, 20 It has been shown that Hsp70 directly inhibits inflammatory processes through the suppression of oxidative stress, directly reduces apoptosis, hyperplasia, as well as decreasing the expression of adhesion molecules that lead to leukocyte extravasation and the manifestation of inflammatory cytokines.16 Higher serum levels of Hsp70 are associated with reduced thickening of the atherosclerotic intima and a lower risk of coronary artery disease.21

Being tested
Exercise
Keywords
Peripheral Arterial Disease, Aerobic Exercise, HSP70
Medical subject headings
Peripheral Arterial Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ExerciseBehavioural

    The experimental group started an exercise program to achieve 65% to 80% of the maximum heart rate by using a pulsometer that measured the heart rate in order to get to the moderate intensity activity goal. The exercise session was 60 minutes long, three times per week, completing 180 minutes per week of moderate intensity exercise, for 12 weeks in total.

Study groups in NCT04743128
Study groupRoleWhat they receive
Control groupNo interventionThe control group received written recommendations to exercise three times per week, for a period of 12 weeks but they did not attend the training sessions.
Exercise groupExperimentalThe experimental group started an exercise program to achieve 65% to 80% of the maximum heart rate by using a pulsometer that measured the heart rate in order to get to the moderate intensity activity goal. The exercise session was 60 minutes long, three times per week, completing 180 minutes per week of moderate intensity exercise, for 12 weeks in total.
Receives: Behavioral: Exercise

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Impact of exercise on expression of Hsp70 in individuals at risk of peripheral arterial disease

    This is a clinical trial where 260 individuals were evaluated by a screening test employing the Ankle-Arm Index (ABI). A number of 220 individuals were not within risk value (0.91 to 0.99 mmHg). In the clinical trial, 32 individuals were included. A control group and an experimental group were formed. Aerobic exercise intervention was performed by the experimental group. The level of Hsp70 was evaluated, physical and clinical measurements were applied at the beginning and at the end of the trial.

    Measured: 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Feb 2021
  2. Study start3 Jun 2019
  3. Primary completion30 Aug 2019
  4. Study completion30 Aug 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
32 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04743128
Sponsor's protocol ID
HSP 70 CLPQ
Acronym
HSP70
Status last verified
Apr 2022
First submitted
27 Jan 2021
Last updated
4 May 2022
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Exercise in people with Peripheral Arterial Disease, run by Universidad Popular Autónoma del Estado de Puebla at 1 site in Mexico.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 May 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Impact of exercise on expression of Hsp70 in individuals at risk of peripheral arterial disease (time frame: 12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2022.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
HSP70 Clinical Trial NCT04743128 | AzTrials